ID   R72/3B
AC   CVCL_C7X8
DR   Wikidata; Q123033308
RX   PubMed=6939365;
RX   PubMed=7440648;
CC   Doubling time: 11.5 hours (PubMed=7440648).
CC   Selected for resistance to: ChEBI; CHEBI_472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; BrdU; BUdR).
CC   Derived from site: In situ; Liver; UBERON=UBERON_0002107.
CC   Cell type: Epithelial cell; CL=CL_0000066.
CC   Breed/subspecies: Wistar; RS=RS_0000955.
OX   NCBI_TaxID=10116; ! Rattus norvegicus (Rat)
HI   CVCL_C7X7 ! R72/3
SX   Male
AG   4W
CA   Transformed cell line
DT   Created: 29-06-23; Last updated: 10-04-25; Version: 5
//
RX   PubMed=6939365; DOI=10.1111/j.1749-6632.1980.tb29538.x;
RA   Avdalovic, Nebojsa
RT   "Bromodeoxyuridine-induced changes in the transformed phenotype.";
RL   Ann. N. Y. Acad. Sci. 349:346-356(1980).
//
RX   PubMed=7440648; DOI=10.1002/jcp.1041040112;
RA   Avdalovic, Nebojsa
RA   Weibel, Joseph
RA   Diamond, Leila
RT   "The effects of 5-bromodeoxyuridine on the growth and morphology of
RT   transformed rat liver cells.";
RL   J. Cell. Physiol. 104:83-96(1980).
//